228 related articles for article (PubMed ID: 32626838)
21. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
22. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Xu H; Cao D; Zhou D; Zhao N; Tang X; Shelat VG; Samant H; Satapathy SK; Tustumi F; Aprile G; He A; Xu X; Ge W
BMC Cancer; 2023 Oct; 23(1):1006. PubMed ID: 37858207
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study.
Iavarone M; Invernizzi F; Ivanics T; Mazza S; Zavaglia C; Sanduzzi-Zamparelli M; Fraile-López M; Czauderna C; Di Costanzo G; Bhoori S; Pinter M; Manini MA; Amaddeo G; Yunquera AF; Piñero F; Blanco Rodríguez MJ; Anders M; Aballay Soteras G; Villadsen GE; Yoon PD; Cesarini L; Díaz-González Á; González-Diéguez ML; Tortora R; Weinmann A; Mazzaferro V; Romero Cristóbal M; Crespo G; Regnault H; De Giorgio M; Varela M; Prince R; Scudeller L; Donato MF; Wörns MA; Bruix J; Sapisochin G; Lampertico P; Reig M
Liver Transpl; 2021 Dec; 27(12):1767-1778. PubMed ID: 34388851
[TBL] [Abstract][Full Text] [Related]
24. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
Rimini M; Yoo C; Lonardi S; Masi G; Granito A; Bang Y; Rizzato MD; Vivaldi C; Ielasi L; Kim HD; Bergamo F; Salani F; Leoni S; Ryoo BY; Ryoo MH; Burgio V; Cascinu S; Casadei-Gardini A
Target Oncol; 2021 Sep; 16(5):653-661. PubMed ID: 34491510
[TBL] [Abstract][Full Text] [Related]
25. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
26. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
[TBL] [Abstract][Full Text] [Related]
27. Combination of systemic immune-inflammation index and albumin-bilirubin grade predict prognosis of regorafenib in unresectable hepatocellular carcinoma.
Teng W; Cheng TA; Lin PT; Lin CC; Lin CY; Lin SM
Am J Cancer Res; 2023; 13(6):2702-2713. PubMed ID: 37424826
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Wang W; Tsuchiya K; Kurosaki M; Yasui Y; Inada K; Kirino S; Yamashita K; Sekiguchi S; Hayakawa Y; Osawa L; Okada M; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Enomoto N; Izumi N
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31601010
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice.
Uchikawa S; Kawaoka T; Aikata H; Kodama K; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Hepatol Res; 2018 Sep; 48(10):814-820. PubMed ID: 29682855
[TBL] [Abstract][Full Text] [Related]
30. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma.
Huang KW; Lee PC; Chao Y; Su CW; Lee IC; Lan KH; Chu CJ; Hung YP; Chen SC; Hou MC; Huang YH
Ther Adv Med Oncol; 2022; 14():17588359221099401. PubMed ID: 35646162
[TBL] [Abstract][Full Text] [Related]
31. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.
Delos Santos S; Udayakumar S; Nguyen A; Ko YJ; Berry S; Doherty M; Chan KKW
Curr Oncol; 2020 Dec; 27(6):300-306. PubMed ID: 33380861
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure.
Kim J; Chang JW; Park JY
J Liver Cancer; 2020 Mar; 20(1):72-77. PubMed ID: 37383058
[TBL] [Abstract][Full Text] [Related]
33. Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma.
Lee IC; Chao Y; Lee PC; Chen SC; Chi CT; Wu CJ; Wu KC; Hou MC; Huang YH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454919
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Bekir Hacioglu M; Kostek O; Karabulut S; Tastekin D; Sezgin Goksu S; Alandag C; Akagunduz B; Bilgetekin I; Caner B; Bilgehan Sahin A; Yildiz B; Kose F; Kaplan MA; Gulmez A; Dogan E; Can Guven D; Gurbuz M; Ergun Y; Karaagac M; Gokcen Demiray A; Turker S; Sakalar T; Ozkul O; Telli TA; Sahin S; Kilickap S; Bilici A; Erdogan B; Cicin I
J BUON; 2020; 25(4):1897-1903. PubMed ID: 33099930
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
36. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Cersosimo RJ
Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Shu Y; Tang Y; Ding Y; Zhang Q
Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.
Merle P; Kudo M; Krotneva S; Ozgurdal K; Su Y; Proskorovsky I
Liver Cancer; 2023 Jun; 12(2):145-155. PubMed ID: 37325487
[TBL] [Abstract][Full Text] [Related]
39. Real-World Lenvatinib
Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
Front Oncol; 2021; 11():737767. PubMed ID: 34760699
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Hiraoka A; Kumada T; Hatanaka T; Tada T; Kariyama K; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Chikara O; Tamai T; Kakizaki S; Tojima H; Nagashima T; Ueno T; Takizawa D; Naganuma A; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
Hepatol Res; 2021 Aug; 51(8):880-889. PubMed ID: 33837620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
